AAP
IMNM icon

Aristotle Atlantic Partners’s Immunome IMNM Stock Holding History

Aristotle Atlantic Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6M Sell
122,675
-2,343
-2% -$50.1K 0.11% 75
2026
Q1 		$2.73M Buy
+125,018
New +$2.78M 0.13% 70

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Aristotle Atlantic Partners's IMNM Position: Q2 2026 in Review

Aristotle Atlantic Partners reduced its Immunome (IMNM) stake by 1.9% in Q2 2026, selling an estimated $50.1K and leaving 122,675 shares worth $2.6M. The position accounts for 0.11% of the portfolio, ranked #75.

Aristotle Atlantic Partners first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.73M in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Aristotle Atlantic Partners held 122,675 shares of Immunome worth $2.6M as of Q2 2026.
  • Aristotle Atlantic Partners sold 2,343 Immunome shares in Q2 2026, an estimated $50.1K.
  • Immunome made up 0.11% of Aristotle Atlantic Partners's portfolio in Q2 2026, its #75 holding.
  • Aristotle Atlantic Partners first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
  • Aristotle Atlantic Partners's Immunome position peaked at $2.73M in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Aristotle Atlantic Partners's 13F filing for Q2 2026, filed 14 Aug 2026.